Literature DB >> 15207759

Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy.

Cristina Tau1, Carlos Mautalen, Cristina Casco, Verónica Alvarez, Marta Rubinstein.   

Abstract

Chronic idiopathic hyperphosphatasia (CIH), or juvenile Paget disease, is a rare disorder characterized by increased bone turnover and progressive enlargement of bones. We report a girl, 6 1/2 years old, with a history of three fractures, short stature, delayed eruption of teeth, and poor hair growth. She had a waddling gait, bone deformities, kyphoscoliosis, hyperlordosis, genu valgum and curvature of her limbs. She also had progressive hearing loss but other cranial nerves were unaffected. Laboratory studies indicated high bone turnover: serum alkaline phosphatase: 4047 IU/l (normal value: 150-550), urinary hydroxyproline: 1205 mg/g creatinine (n.v.: 60-160), and urinary CrossLaps: 4360 microg/mmol creatinine (n.v.: 450-2100). Radiographs demonstrated generalized skeletal involvement with osteoectasia (expansion) of long bones, diffuse sclerosis, cotton wool appearance of the skull, absence of mastoid pneumatization, and crushed dorsal and lumbar vertebrae. Iliac crest biopsy was compatible with CIH. Cyclical intravenous pamidronate (1 mg/kg/day during 3 h, 3 consecutive days at 2- to 3-month intervals) was administered during 2 years with oral calcium 500 mg and vitamin D 1000 IU/day. Oral pamidronate was added after 11 months of i.v. therapy. Treatment-induced remarkable clinical and radiographic improvement with normalization of bone markers of osteoblastic and osteoclastic activity, including bone alkaline phosphatase, urinary hydroxyproline, and urinary CrossLaps.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207759     DOI: 10.1016/j.bone.2004.03.013

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

Review 2.  [Hyperphosphatasia and hypophosphatasia in childhood].

Authors:  P Drees; D Schmidt; T Lewens; T Vetter; A Meurer
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

3.  Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.

Authors:  Michael P Whyte; Cristina Tau; William H McAlister; Xiafang Zhang; Deborah V Novack; Virginia Preliasco; Eduardo Santini-Araujo; Steven Mumm
Journal:  Bone       Date:  2014-07-23       Impact factor: 4.398

4.  Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease.

Authors:  E N Gonc; A Ozon; G Buyukyilmaz; A Alikasifoglu; O P Simsek; N Kandemir
Journal:  Osteoporos Int       Date:  2018-03-03       Impact factor: 4.507

5.  Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation.

Authors:  Forough Saki; Zohreh Karamizadeh; Shiva Nasirabadi; Steven Mumm; William H McAlister; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

6.  Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing.

Authors:  Judit Donáth; Gábor Speer; János P Kósa; Kristóf Árvai; Bernadett Balla; Péter Juhász; Péter Lakatos; Gyula Poór
Journal:  Croat Med J       Date:  2015-04       Impact factor: 1.351

7.  Chronic idiopathic hyperphosphatasia with unusual dental findings - A case report.

Authors:  Cheriya K Sreejan; Nair Gopakumar; Gogineni Subhas Babu
Journal:  J Clin Exp Dent       Date:  2012-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.